These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 34713799)

  • 1. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021.
    Stringhini S; Zaballa ME; Pullen N; Perez-Saez J; de Mestral C; Loizeau AJ; Lamour J; Pennacchio F; Wisniak A; Dumont R; Baysson H; Richard V; Lorthe E; Semaani C; Balavoine JF; Pittet D; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe K; Kaiser L; Guessous I;
    Euro Surveill; 2021 Oct; 26(43):. PubMed ID: 34713799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
    Zaballa ME; Perez-Saez J; de Mestral C; Pullen N; Lamour J; Turelli P; Raclot C; Baysson H; Pennacchio F; Villers J; Duc J; Richard V; Dumont R; Semaani C; Loizeau AJ; Graindorge C; Lorthe E; Balavoine JF; Pittet D; Schibler M; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe KM; Kaiser L; Trono D; Stringhini S; Guessous I;
    Lancet Reg Health Eur; 2023 Jan; 24():100547. PubMed ID: 36474728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: A cross-sectional study.
    Koirala A; McRae J; Britton PN; Downes M; Prasad SA; Nicholson S; Winkler NE; O'Sullivan MVN; Gondalwala F; Castellano C; Carey E; Hendry A; Crawford N; Wadia U; Richmond P; Marshall HS; Clark JE; Francis JR; Carr J; Bartlett A; McMullan B; Skowno J; Hannah D; Davidson A; von Ungern-Sternberg BS; Lee-Archer P; Burgoyne LL; Waugh EB; Carlin JB; Naing Z; Kerly N; McMinn A; Hunter G; Heath C; D'Angelo N; Finucane C; Francis LA; Dougherty S; Rawlinson W; Karapanagiotidis T; Cain N; Brizuela R; Blyth CC; Wood N; Macartney K
    PLoS One; 2024; 19(9):e0300555. PubMed ID: 39292730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
    Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.
    Stringhini S; Wisniak A; Piumatti G; Azman AS; Lauer SA; Baysson H; De Ridder D; Petrovic D; Schrempft S; Marcus K; Yerly S; Arm Vernez I; Keiser O; Hurst S; Posfay-Barbe KM; Trono D; Pittet D; Gétaz L; Chappuis F; Eckerle I; Vuilleumier N; Meyer B; Flahault A; Kaiser L; Guessous I
    Lancet; 2020 Aug; 396(10247):313-319. PubMed ID: 32534626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study.
    Amati R; Piumatti G; Franscella G; Buttaroni P; Camerini AL; Corna L; Levati S; Fadda M; Fiordelli M; Annoni AM; Bezani K; Amendola A; Fragoso Corti C; Sabatini S; Kaufmann M; Frei A; Puhan MA; Crivelli L; Albanese E; On Behalf Of The Corona Immunitas Ticino Study Group
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased breadth and neutralization of antibodies against SARS-CoV-2 variants after infection and vaccination: A serosurveillance study in pediatric patients of Southern Switzerland.
    Mazzara C; Bassi J; Silacci-Fregni C; Muoio F; Passini N; Corti D; Simonetti GD; Vanoni F; Kottanattu L; Piccoli L
    Eur J Pediatr; 2024 Mar; 183(3):1425-1434. PubMed ID: 38175262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.
    Kislaya I; Gonçalves P; Ramalhete S; Barreto M; Torres AR; Gaio V; Gómez V; Manita C; Almeida Santos J; Soeiro S; De Sousa R; Melo A; Henriques C; Guiomar R; Rodrigues AP;
    Acta Med Port; 2023 Jan; 36(1):5-14. PubMed ID: 36288645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada.
    Skowronski DM; Kaweski SE; Irvine MA; Kim S; Chuang ESY; Sabaiduc S; Fraser M; Reyes RC; Henry B; Levett PN; Petric M; Krajden M; Sekirov I
    CMAJ; 2022 Dec; 194(47):E1599-E1609. PubMed ID: 36507788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.
    Murhekar MV; Bhatnagar T; Thangaraj JWV; Saravanakumar V; Santhosh Kumar M; Selvaraju S; Rade K; Kumar CPG; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chakraborty D; Chopra V; Das D; Devi KR; Dwivedi GR; Jain A; Khan SMS; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Ramesh T; Rangaraju C; Turuk J; Yadav S; Bhargava B;
    PLoS Med; 2021 Dec; 18(12):e1003877. PubMed ID: 34890407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
    Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
    JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Ortho VITROS and Roche Elecsys S and NC Immunoassays for SARS-CoV-2 Serosurveillance Applications.
    Sulaeman H; Grebe E; Dave H; McCann L; Di Germanio C; Sanghavi A; Sclar V; Bougie DW; Chatelain G; Biggerstaff BJ; Jones JM; Thornburg NJ; Kleinman S; Stone M; Busch MP
    Microbiol Spectr; 2023 Aug; 11(4):e0323422. PubMed ID: 37347180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
    He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
    Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Newborn Dried Blood Spots to Ascertain Seroprevalence of SARS-CoV-2 Antibodies Among Individuals Giving Birth in New York State, November 2019 to November 2021.
    Damjanovic A; Styer LM; Nemeth K; Yauney E; Rock JM; Bievenue R; Hoen R; Ehrbar D; Kay DM; Caggana M; Parker MM
    JAMA Netw Open; 2022 Aug; 5(8):e2227995. PubMed ID: 35994287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021.
    Kao S-YZ; Nycz E; Benoit TJ; Clarke KEN; Jones JM
    Microbiol Spectr; 2024 Aug; 12(8):e0012324. PubMed ID: 38869287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.
    Woudenberg T; Pelleau S; Anna F; Attia M; Donnadieu F; Gravet A; Lohmann C; Seraphin H; Guiheneuf R; Delamare C; Stefic K; Marlet J; Brochot E; Castelain S; Augereau O; Sibilia J; Dubos F; Meddour D; Guen CG; Coste-Burel M; Imbert-Marcille BM; Chauvire-Drouard A; Schweitzer C; Gatin A; Lomazzi S; Joulié A; Haas H; Cantais A; Bertholon F; Chinazzo-Vigouroux MF; Abdallah MS; Arowas L; Charneau P; Hoen B; Demeret C; Werf SV; Fontanet A; White M
    EBioMedicine; 2021 Aug; 70():103495. PubMed ID: 34304047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.